Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; and Belixos PROTECT for the needs of sun-damaged skin. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Show more
Leverkusen, DE
Size (employees)
125 (est)+33%
Biofrontera was founded in 2012 and is headquartered in Leverkusen, DE
Report incorrect company information

Biofrontera Office Locations

Biofrontera has an office in Leverkusen
Leverkusen, DE (HQ)
201 Hemmelrather Weg
Show all (1)
Report incorrect company information

Biofrontera Financials and Metrics

Biofrontera Financials

Market capitalization (30-Oct-2017)

135.6 m

Closing share price (30-Oct-2017)

Biofrontera's current market capitalization is €135.6 m.
Show all financial metrics
Report incorrect company information